[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.106.142. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Vocal Cord Scarring—Functional Response to Autologous Adipose Tissue–Derived Stromal Vascular Fraction (ADSVF) Injection

Vocal cord scarring can be disabling and resistant to treatment. Stem cell treatment might be effective but is expensive and requires weeks to culture. In contrast, autologous ADSVF refers to a mix of cells (mesenchymal stem cells [MSCs] or adipose-derived stem cells [ADSCs]), fibroblasts, leukocytes, endothelial cells, and progenitors and pericytes) that can be harvested in hours from enzymatic digestion of adipose. Experimental and clinical reports suggest ADSVF has antifibrotic effects, mainly attributed to the stem cell fraction. Researchers assessed the feasibility of using ADSVF for treatment of vocal cord scarring in a phase 1 clinical trial and concluded the treatment was safe and potentially effective. This video shows its functional effects in a patient with congenital scarring (sulcus). Before, the patient’s voice was breathy and slightly hoarse during reading and when voicing a sustained vowel /a/, with a short maximum phonation duration. After treatment, the patient’s voice was clearer without breathiness or hoarseness, and her maximum phonation time was longer. Click the related article link for a complete discussion of the intervention and of other patients’ outcomes.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Close

Name Your Search

Save Search
Close
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
Close